剖宫产术皮下皮肤缝合采用聚卡普隆-25与聚乳糖-910的比较:一项随机对照试验
这项双盲、单中心随机对照试验纳入200例行剖宫产(择期和急诊)的妇女,比较聚卡普隆-25(3-0)与聚乳糖-910(4-0)皮下缝合。两组复合伤口并发症相似(16 vs 10;P=.293;RR 1.28;95%CI 0.91-1.79),但聚卡普隆-25组术后3天和6周疼痛评分显著更低(P=.023和P=.033)。
要点
- 聚卡普隆-25(3-0)与聚乳糖-910(4-0)皮下缝合的复合伤口并发症无显著差异。
- 聚卡普隆-25组术后3天和6周疼痛视觉模拟评分均显著低于聚乳糖-910组。
- 两组术后6周观察者瘢痕评估评分和患者瘢痕评估评分无显著差异。
核心结论
- 在行Pfannenstiel切口剖宫产的非肥胖妇女中,聚卡普隆-25(3-0)与聚乳糖-910(4-0)皮下缝合在复合伤口并发症和美容外观方面相当。
- 聚卡普隆-25组术后3天和6周疼痛视觉模拟评分显著低于聚乳糖-910组。
研究设计与样本
- 双盲、单中心、随机对照试验,纳入200例行剖宫产(择期和急诊)的妇女,随机分为聚卡普隆-25(3-0)皮下缝合组和聚乳糖-910(4-0)皮下缝合组。
- 样本量估算:以复合伤口并发症率从15.8%降至3.6%、把握度0.80、双侧α=0.05计算,每组需90例,考虑失访后每组选100例。
- 所有妇女接受相似的术前和术后护理。
主要发现
- 复合伤口并发症(包括手术部位感染、血肿、血清肿、需要重新缝合或因伤口并发症再入院):聚卡普隆-25组16例 vs 聚乳糖-910组10例(P=.293;相对风险1.28;95%置信区间0.91-1.79)。
- 手术部位感染:聚卡普隆-25组8例 vs 聚乳糖-910组7例(P=1.000;相对风险1.08;95%置信区间0.64-1.83)。
- 血肿:聚卡普隆-25组1例 vs 聚乳糖-910组2例(P=.561;相对风险0.66;95%置信区间0.13-3.31)。
- 血清肿:聚卡普隆-25组8例 vs 聚乳糖-910组2例(P=.052;相对风险1.65;95%置信区间1.17-2.33)。
- 需要重新缝合:聚卡普隆-25组4例 vs 聚乳糖-910组3例(P=.700;相对风险1.15;95%置信区间0.60-2.22)。
关键数值与推荐
- 复合伤口并发症率:聚卡普隆-25组16% vs 聚乳糖-910组10%(P=.293;相对风险1.28;95%置信区间0.91-1.79)。
- 手术部位感染率:聚卡普隆-25组8% vs 聚乳糖-910组7%(P=1.000;相对风险1.08;95%置信区间0.64-1.83)。
- 血清肿发生率:聚卡普隆-25组8% vs 聚乳糖-910组2%(P=.052;相对风险1.65;95%置信区间1.17-2.33)。
- 术后3天疼痛视觉模拟评分:聚卡普隆-25组3.2±1.0 vs 聚乳糖-910组3.6±1.2(P=.023)。
- 术后6周疼痛视觉模拟评分:聚卡普隆-25组1.6±0.8 vs 聚乳糖-910组1.7±0.9(P=.033)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cesarean delivery is a commonly performed surgical procedure worldwide. There is limited good-quality evidence regarding subcuticular skin closure with absorbable sutures in transverse incisions after cesarean delivery. OBJECTIVE: This study aimed to compare poliglecaprone-25 (3-0) and polyglactin-910 (4-0) sutures for subcuticular skin closure in Pfannenstiel incisions among women undergoing cesarean delivery. STUDY DESIGN: In this double-blind, single-center, randomized controlled trial among women undergoing cesarean delivery (elective and emergency), 200 women were randomized (Group 1-subcuticular skin closure with poliglecaprone-25 [3-0] vs Group 2-subcuticular skin closure with polyglactin-910 [4-0]). All women received similar preoperative and postoperative care. A sample size of 200 women was selected with the aim of reducing the composite wound complication rate from 15.8% to 3.6% with a power of 0.80 and a 2-tailed α of 0.05. Thus, 90 women were required in each group, but 100 were selected to account for attrition. RESULTS: Composite wound complications (including surgical site infection, hematoma, seroma, need for resuturing or readmission for wound complications) were similar in the 2 groups (Group 1 vs 2: 16 vs 10; P=.293; relative risk, 1.28; 95% confidence interval, 0.91-1.79). Surgical site infection (8 vs 7; P=1.000; relative risk, 1.08; 95% confidence interval, 0.64-1.83), hematoma (1 vs 2; P=.561; relative risk, 0.66; 95% confidence interval, 0.13-3.31), seroma (8 vs 2; P=.052; relative risk, 1.65; 95% confidence interval, 1.17-2.33), need for resuturing (4 vs 3; P=.700; relative risk, 1.15; 95% confidence interval, 0.60-2.22), and need for readmission (4 vs 4; P=1.000) were similar in the 2 groups. Pain score on the visual analog scale at 3 days (3.2±1.0 vs 3.6±1.2) and 6 weeks after operation (1.6±0.8 vs 1.7±0.9;) was significantly lower in Group 1 (P=.023 and P=.033, respectively). There was no difference between observer and patient scar assessment scores measured at 6 weeks after operation (P=.069 and P=.431, respectively). CONCLUSION: Poliglecaprone-25 (3-0) and polyglactin-910 (4-0) subcuticular sutures were comparable regarding composite wound complications (surgical site infection, hematoma, seroma, wound separation or re-suturing, need for readmission) and cosmetic appearance (patient scar assessment score & observer scar assessment score) related to skin closure among women undergoing cesarean delivery through a Pfannenstiel incision in nonobese women (average body mass index, 25).
引用
- Sharma C, Sharma S, Soni A, et al. Subcuticular skin closure at cesarean delivery with poliglecaprone-25 vs polyglactin-910: a randomized controlled trial. Am J Obstet Gynecol MFM. 2023. PMID: 38109995. doi:10.1016/j.ajogmf.2023.101256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。